Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

November 04, 2026

Performance

52-Week Range 66.7% below 52-week high

159.63

156.0052W Low 479.7952W High

1 Week 21.1% below 1-week high

156.001W Low 202.371W High

Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) traded between $156.00 and $479.79 over the past 52 weeks and last traded at $159.63, 66.7% below its 52-week high. Over the past week it ranged between $156.00 and $202.37.

Past 12 Months

-8.3%

-27.4%

-30.2%

-47.3%

-60.1%

-62.3%

1W -$14.37

1M -$60.26

3M -$69.09

6M -$143.37

YTD -$240.54

1Y -$263.84

ALNY was -62.3% over the past year, -47.3% over six months, -60.1% year to date, -8.3% in the last week.

12 Months vs Market

ALNY

-62.3%

DIA

+9.4%

SPY

+8.8%

QQQ

+5.2%

IWM

+12.4%

Over the past 12 months ALNY returned -62.3% versus DIA (Dow) +9.4%, SPY (S&P 500) +8.8%, QQQ (Nasdaq 100) +5.2% and IWM (Russell 2000) +12.4%.

Volume & Liquidity 0.95× 3-mo avg

Today 1,800,127 3-mo avg 1.9M

6.2M

2.4M

1.9M

1.7M

YTD

1.6M

1.5M

ALNY most recently traded 1,800,127 shares against a 3-month average daily volume of 1.9M.

More News

3 Nasdaq-100 Stocks That Can Double, According to Wall Street ↗

November 04, 2026

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

November 03, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum ↗

October 16, 2026

Via Chartmill

Top US Stock Gainers and Losers for Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Alnylam (ALNY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Alnylam Pharmaceuticals Q3 Earnings Call Highlights ↗

October 29, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ↗

October 08, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Premarket Gainers and Losers on Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

October 29, 2026

From Alnylam Pharmaceuticals

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial ↗

October 26, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

October 23, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

October 15, 2026

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗

September 19, 2026

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Via Benzinga

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026